Literature DB >> 17636604

WITHDRAWN: Clomiphene or tamoxifen for idiopathic oligo/asthenospermia.

P Vandekerckhove1, R Lilford, A Vail, E Hughes.   

Abstract

BACKGROUND: Oligo-astheno-teratospermia (sperm of low concentration, reduced motility and increased abnormal morphology) of unknown cause is common and the need for treatment is felt by patients and doctors alike. As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility.The administration of anti-oestrogens is a common treatment because anti oestrogens interfere with the normal negative feedback of sex steroids at hypothalamic and pituitary levels in order to increase endogenous gonadotropin-releasing hormone secretion from the hypothalamus and FSH and LH secretion directly from the pituitary. In turn, FSH and LH stimulate Leydig cells in the testes, and this has been claimed to lead to increased local testosterone production, thereby boosting spermatogenesis with a possible improvement in fertility. There may also be a direct effect of anti-oestrogens on testicular spermatogenesis or steroidogenesis. This review considers the available evidence of the effect of both Clomiphene citrate and tamoxifen, both of which have a predominant anti-oestrogenic effect, for idiopathic oligo and/or asthenospermia.
OBJECTIVES: The objective was to assess the effects of treating subfertile men with anti-oestrogens (clomiphene or tamoxifen) on pregnancy rates among couples where subfertility has been attributed to idiopathic oligo- and/or asthenospermia. SEARCH STRATEGY: The Cochrane Subfertility Review Group specialised register of controlled trials was searched". SELECTION CRITERIA: Randomised trials of anti-oestrogen therapy for 3 months or more compared to placebo or no placebo for subfertile males among couples where subfertility is attributed to male factor. DATA COLLECTION AND ANALYSIS: Data were extracted independently by two reviewers. Any differences were resolved with a third reviewer. MAIN
RESULTS: Ten studies involving 738 men were included. Five of the trials did not specify method of randomisation. Anti-oestrogens had a positive effect on endocrinal outcomes, such as serum testosterone levels. In trials with secure randomisation there was no difference in the pregnancy rate between the anti-oestrogen groups and the control groups (odds ratio 1.26, 95% confidence interval 0.99 to 1.56). The overall pregnancy rate for these five trials was 15.4% compared to the spontaneous rate of 12.5% in the control groups. These odds increased to 1.56 (95% confidence interval 0.99 to 2.19) when all 10 trials were included, but this result is likely to be artificially inflated. AUTHORS'
CONCLUSIONS: Anti-oestrogens appear to have a beneficial effect on endocrinal outcomes, but there is not enough evidence to evaluate the use of anti-oestrogens for increasing the fertility of males with idiopathic oligo-asthenospermia.[This abstract was prepared centrally.].

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636604     DOI: 10.1002/14651858.CD000151

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  9 in total

Review 1.  [Drug therapy options for oligoasthenoteratozoospermia syndrome].

Authors:  M Trottmann; F M Köhn; M Dickmann; C G Stief; A J Becker
Journal:  Urologe A       Date:  2011-01       Impact factor: 0.639

Review 2.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

3.  Effects of di-n-butyl phthalate on male rat reproduction following pubertal exposure.

Authors:  Ai-Mei Bao; Xiao-Ming Man; Xue-Jiang Guo; Hui-Bin Dong; Fu-Qiang Wang; Hong Sun; Yu-Bang Wang; Zuo-Min Zhou; Jia-Hao Sha
Journal:  Asian J Androl       Date:  2011-08-15       Impact factor: 3.285

Review 4.  Contemporary concepts in the evaluation and management of male infertility.

Authors:  Kathleen Hwang; R Chanc Walters; Larry I Lipshultz
Journal:  Nat Rev Urol       Date:  2011-01-18       Impact factor: 14.432

5.  Editorial Commentary.

Authors:  Ranjith Ramasamy; Jason M Scovell; Larry I Lipshultz
Journal:  Urol Pract       Date:  2015-04-11

6.  Abnormal Hypermethylation of the VDAC2 Promoter is a Potential Cause of Idiopathic Asthenospermia in Men.

Authors:  Aiming Xu; Yibo Hua; Jianzhong Zhang; Wei Chen; Kai Zhao; Wei Xi; Hainan Wang; Jianzheng Fang; Shifeng Su; Min Tang; Bianjiang Liu; Zengjun Wang
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

7.  More attention should be paid to the treatment of male infertility with drugs--testosterone: to use it or not?

Authors:  Hong-Jun Li
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

Review 8.  Estrogens as antioxidant modulators in human fertility.

Authors:  A Mancini; S Raimondo; M Persano; C Di Segni; M Cammarano; G Gadotti; A Silvestrini; A Pontecorvi; E Meucci
Journal:  Int J Endocrinol       Date:  2013-11-20       Impact factor: 3.257

Review 9.  Empirical medical therapy in idiopathic male infertility: Promise or panacea?

Authors:  Jae Hung Jung; Ju Tae Seo
Journal:  Clin Exp Reprod Med       Date:  2014-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.